The patient has been on a peptide for eight weeks. They feel no different. They want to know whether to increase the dose, switch compounds, or stop.
Increasing the dose is usually the wrong first move, because in most of these cases the peptide was never the limiting factor.
Reason One: The Substrate Is Wrong
This is the most common and the most correctable.
Dr. Jennifer Thomas-Goering makes the physiological case directly: “To get a lot of these benefits from the peptides, it's not just taking the peptide. It's doing the other hard work that goes along with it, like your rest, your nutrition.”
The specific lever she names is autonomic and adrenal: “Getting the sympathetic stimulation and your cortisol levels to go down so that the peptides are then able to work.”
A patient running high sympathetic tone on poor sleep, with cortisol to match, is asking a signalling molecule to work against their own physiology. The peptide is not failing so much as being outvoted.
Reason Two: The Hormone Picture Was Never Checked
Thomas-Goering is explicit that this is a prerequisite rather than a refinement, and her example is the common one.
“You can't just say, hey, I'm going to put you on these three peptides because you want to have stronger bones and bigger muscles. But I have to know what your testosterone level is. I have to know what some of your cortisol levels are and make sure that those are optimized, because otherwise the peptides aren't effective.”
If a growth-axis or body-composition peptide was started without baseline hormone status, there is no way to know whether the compound underperformed or whether it was deployed into a hormonal environment that could not support the outcome. That is a missing measurement, not a failed drug.
Reason Three: The First 90 Percent Was Skipped
Dr. Stephen Cosentino, Empire's founder and president, frames the proportion that explains most disappointment in this category: peptides are “the last 10 percent,” and the first 90 percent is general health — cardiovascular, metabolic, cancer screening, muscle preservation, prediabetes.
A peptide layered on top of untreated metabolic disease, no resistance training and inadequate protein is being asked to substitute for the foundation rather than optimize it. We cover that sequence in peptides are the last 10 percent.
Reason Four: There Was Never Much Evidence for This One
Sometimes the honest answer is that the compound was never likely to do what was hoped.
Many peptides in circulation sit in what Cosentino calls the promoted bucket — marketed well ahead of their human data. If the patient started something with animal data and an enthusiastic supplier behind it, “it isn't working” may simply be the expected result honestly reported.
This is easier to say at week eight if the evidence level was stated at week zero.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Functional & Regenerative Medicine courses — live patients, expert faculty, and ongoing mentorship.
Reason Five: Nobody Defined What Working Would Look Like
A large share of “it isn't working” is really “we never agreed what working meant.”
Energy, sleep quality, recovery and body composition all move slowly and are all easy to misremember. Without a baseline and a defined endpoint, both of you are comparing today against a recollection — and recollection is unreliable in both directions.
Set the endpoint and the review date when you start: a symptom scale, a measurement, a photograph, a lab, a functional test. Then the eight-week conversation has data in it.
Reason Six: Source and Handling
Worth asking plainly, without accusation: where did it come from, and how has it been stored?
Dr. Chris Croley, Empire's Chief Medical Officer, notes the real-world consequence of patients sourcing independently — unapproved suppliers have produced reports of people “injecting nothing,” and of non-sterile product causing sepsis and cellulitis. A compound that contains less than the label claims will underperform exactly like a compound that does not work.
Storage and reconstitution matter too, and patients rarely volunteer that they left a vial out.
The Workup Before You Change the Dose
- Check sleep, stress and cortisol. The substrate first.
- Check hormone status if it was not baselined.
- Audit the foundation — training, protein, metabolic markers, screening.
- Re-state the evidence level for that specific compound, honestly.
- Ask what endpoint you agreed, and whether it was ever measured.
- Ask about source, storage and reconstitution.
- Only then consider dose, route or compound.
Escalating dose before that list is how patients end up on more compounds at higher cost with the same result — and how a practice acquires a reputation for selling rather than treating.
Empire teaches the assessment, the receptor science and the clinical application across the anti-aging and regenerative medicine academy.
Frequently Asked Questions
Why are my peptides not working?
The most common reasons are that the underlying physiology was not addressed — sleep, stress and cortisol, or unmeasured hormone status — that foundational health was skipped, that the specific compound never had much human evidence behind it, or that no endpoint was defined at the start so there is nothing to compare against.
Should the dose be increased if there is no effect?
Not as a first step. Increasing dose before checking the substrate, the hormone picture, the evidence level for that compound and the product source usually adds cost and risk without addressing the actual limiting factor.
How long before a peptide should show an effect?
It depends entirely on the compound and the endpoint, which is why the endpoint and review date should be agreed before starting. Body composition and recovery move slowly and are easy to misjudge from memory alone.
Could the product itself be the problem?
Yes. Patients sourcing independently from unapproved suppliers may receive product that is underdosed, mislabelled or non-sterile, and there are documented harms from that route. Source, storage and reconstitution belong in the history.
Disclaimer
This article is educational and intended for licensed clinicians. It is not medical advice and does not establish a clinician-patient relationship. Regulatory status varies by compound and changes over time; verify current status before prescribing. Nothing here should delay appropriate investigation of an underlying medical condition.
Claim Your Prize!